Key Points
- CEO Shane Schaffer purchased 6,809 shares on Feb. 6 at about $5.04 per share (a $34,317 purchase), boosting his holdings 202% to 10,175 shares valued around $51,282, according to an SEC filing.
- Other insiders also bought shares the same day (CFO Jennifer Callahan, EVP Matthew Brams, and Director Peter Werth), representing notable insider accumulation and a management vote of confidence.
- Despite the insider buying, Cingulate is a small-cap biopharma (~$50.8M market cap) with negative earnings and a recent EPS miss; analysts are mixed (average "Moderate Buy" with a $31.33 consensus target) and earlier short interest rose to ~5.5% of the float.
Cingulate Inc. (NASDAQ:CING - Get Free Report) CFO Jennifer Callahan purchased 4,864 shares of the company's stock in a transaction that occurred on Friday, February 6th. The shares were acquired at an average cost of $5.04 per share, for a total transaction of $24,514.56. Following the completion of the transaction, the chief financial officer directly owned 5,059 shares of the company's stock, valued at $25,497.36. This trade represents a 2,494.36% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.
Cingulate Price Performance
NASDAQ:CING opened at $6.82 on Wednesday. The stock has a market cap of $50.81 million, a PE ratio of -1.88 and a beta of -0.75. Cingulate Inc. has a fifty-two week low of $3.20 and a fifty-two week high of $7.92. The stock's 50-day moving average is $4.92 and its two-hundred day moving average is $4.30.
Cingulate (NASDAQ:CING - Get Free Report) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($1.35) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.55). On average, equities research analysts anticipate that Cingulate Inc. will post -11.69 earnings per share for the current year.
Institutional Investors Weigh In On Cingulate
A number of large investors have recently bought and sold shares of CING. XTX Topco Ltd acquired a new position in Cingulate during the 2nd quarter worth $45,000. Bank of America Corp DE grew its position in shares of Cingulate by 283.1% in the second quarter. Bank of America Corp DE now owns 7,501 shares of the company's stock valued at $31,000 after purchasing an additional 5,543 shares during the last quarter. Quantum Private Wealth LLC increased its stake in shares of Cingulate by 140.0% in the third quarter. Quantum Private Wealth LLC now owns 24,000 shares of the company's stock worth $94,000 after purchasing an additional 14,000 shares during the period. Soltis Investment Advisors LLC acquired a new position in shares of Cingulate during the 4th quarter worth about $43,000. Finally, Geode Capital Management LLC lifted its position in shares of Cingulate by 43.9% during the 4th quarter. Geode Capital Management LLC now owns 61,035 shares of the company's stock worth $265,000 after purchasing an additional 18,629 shares during the last quarter. 41.31% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of equities analysts have recently weighed in on CING shares. Ascendiant Capital Markets dropped their price target on shares of Cingulate from $62.00 to $58.00 and set a "buy" rating on the stock in a research note on Monday, December 8th. Weiss Ratings restated a "sell (e+)" rating on shares of Cingulate in a research note on Wednesday, January 21st. Finally, Roth Mkm cut their price target on Cingulate from $17.00 to $16.00 and set a "buy" rating for the company in a research note on Wednesday, November 19th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $31.33.
View Our Latest Report on CING
Key Cingulate News
Here are the key news stories impacting Cingulate this week:
- Positive Sentiment: CEO Shane J. Schaffer bought 6,809 shares at an average price of ~$5.04, raising his stake >200% — a clear insider vote of confidence. Cingulate CEO Shane Schaffer Purchases 6,809 Shares
- Positive Sentiment: CFO Jennifer L. Callahan purchased 4,864 shares (~$5.04), increasing her holding materially — reinforces the management accumulation theme. CFO SEC Filing
- Positive Sentiment: EVP Matthew Brams acquired 1,946 shares at ~$5.04, a meaningful increase in his stake. EVP SEC Filing
- Positive Sentiment: Director Peter J. Werth bought 19,455 shares at ~$5.04 (≈$98k), materially increasing his position — adds institutional‑style endorsement from the board. Director SEC Filing
- Neutral Sentiment: A MedicalXpress article reports impaired brain energy metabolism in people with post‑COVID — relevant scientifically but only indirectly material to Cingulate unless tied to the company’s programs. Study shows impaired energy metabolism in the brains of people with post-COVID
- Neutral Sentiment: Short‑interest reporting shows an apparent “0 shares” figure on Feb. 10 (likely a reporting glitch), creating temporary data uncertainty for traders; treat this datapoint cautiously.
- Negative Sentiment: Earlier (Jan. 30) short interest rose to ~389,923 shares (~5.5% of float) with a short‑ratio near 1 day — active short selling that can amplify downside and cap rallies if selling intensifies.
About Cingulate
(
Get Free Report)
Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
